Literature DB >> 10593517

Critical Lym-1 binding residues on polymorphic HLA-DR molecules.

L M Rose1, C T Deng, S L Scott, C Y Xiong, K R Lamborn, P H Gumerlock, G L DeNardo, C F Meares.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10593517     DOI： 10.1016/s0161-5890(99)00083-8

Source DB:  PubMed          Journal:  Mol Immunol        ISSN： 0161-5890            Impact factor:   4.407


× No keyword cloud information.
  7 in total

1.  Is high-dose radioimmunotherapy needed in non-Hodgkin's lymphoma? For.

Authors:  Thomas M Behr
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-09       Impact factor: 9.236

2.  Nanomolecular HLA-DR10 antibody mimics: A potent system for molecular targeted therapy and imaging.

Authors:  Gerald L DeNardo; Arutselvan Natarajan; Saphon Hok; Gary Mirick; Sally J DeNardo; Michele Corzett; Vladimir Sysko; Joerg Lehmann; Laurel Beckett; Rod Balhorn
Journal:  Cancer Biother Radiopharm       Date:  2008-12       Impact factor: 3.099

3.  Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.

Authors:  Rhona Stein; Zhengxing Qu; Susan Chen; David Solis; Hans J Hansen; David M Goldenberg
Journal:  Blood       Date:  2006-06-15       Impact factor: 22.113

4.  High-Performance Concurrent Chemo-Immuno-Radiotherapy for the Treatment of Hematologic Cancer through Selective High-Affinity Ligand Antibody Mimic-Functionalized Doxorubicin-Encapsulated Nanoparticles.

Authors:  Kin Man Au; Rod Balhorn; Monique C Balhorn; Steven I Park; Andrew Z Wang
Journal:  ACS Cent Sci       Date:  2018-12-26       Impact factor: 14.553

Review 5.  In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy.

Authors:  Tianqing Xin; Li Cheng; Chuchao Zhou; Yimeng Zhao; Zhenhua Hu; Xiaoyan Wu
Journal:  Front Oncol       Date:  2022-02-10       Impact factor: 6.244

6.  Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell Lymphoma.

Authors:  Long Zheng; Peisheng Hu; Brandon Wolfe; Caryn Gonsalves; Luqing Ren; Leslie A Khawli; Harvey R Kaslow; Alan L Epstein
Journal:  Int J Mol Sci       Date:  2017-12-20       Impact factor: 5.923

7.  Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers.

Authors:  Rod Balhorn; Monique Cosman Balhorn
Journal:  Oncotarget       Date:  2020-09-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.